Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT1 | Q9H9B1 | 4/20 | 0.62 |
| ▸ | EHMT2 | Q96KQ7 | 3/20 | 0.62 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.60 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.60 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.60 |
| ▸ | P2RY1 | P47900 | 4/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.58 |
| ▸ | SRC | P12931 | 2/20 | 0.58 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.58 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.58 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.58 |
| ▸ | LDHA | P00338 | 1/20 | 0.58 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.58 |
| ▸ | FBP1 | P09467 | 1/20 | 0.58 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.58 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.58 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6569310 | 0.83 | ADORA1 (0.73) | ADORA1ADORA3ADORA2AADORA2BP2RY1 | |
| SCHEMBL120562 | 0.82 | ADORA3 (0.68) | EHMT1EHMT2ADORA1ADORA3ADORA2A | |
| SCHEMBL939593 | 0.82 | ADORA1 (0.71) | ADORA1ADORA3ADORA2AADORA2BP2RY1 | |
| SCHEMBL8708990 | 0.82 | ADORA1 (0.71) | EHMT1ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL940814 | 0.81 | EHMT1 (0.59) | EHMT1EHMT2ADORA1ADORA3ADORA2A | |
| SCHEMBL13268990 | 0.81 | EHMT1 (0.71) | EHMT1EHMT2ADORA1ADORA3ADORA2A | |
| SCHEMBL120551 | 0.81 | ADORA3 (0.69) | EHMT1EHMT2ADORA1ADORA3ADORA2A | |
| SCHEMBL2294351 | 0.81 | ADORA1 (0.58) | EHMT1EHMT2ADORA1ADORA3ADORA2A | |
| SCHEMBL28978257 | 0.80 | P2RY1 (0.65) | ADORA1ADORA3ADORA2AADORA2BP2RY1 | |
| SCHEMBL5063589 | 0.79 | ADORA1 (0.65) | EHMT1EHMT2ADORA1ADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060205671-A1 | Compositions and methods for use of a protease inhibitor and adenosine for preventing organ ischemia and reperfusion injury | EMORY UNIVERSITY | 2006-09-14 | — | — | US | claimed |
| EP-1638579-A2 | COMPOSITIONS AND METHODS FOR USE OF A PROTEASE INHIBITOR AND ADENOSINE FOR PREVENTING ORGAN ISCHEMIA AND REPERFUSION INJURY | EMORY UNIVERSITY (US) | 2006-03-29 | — | — | EP | claimed |
| WO-2005003150-A2 | COMPOSITIONS AND METHODS FOR USE OF A PROTEASE INHIBITOR AND ADENOSINE FOR PREVENTING ORGAN ISCHEMIA AND REPERFUSION INJURY | EMORY UNIVERSITY (US) | 2005-01-13 | — | — | WO | claimed |
| US-10342818-B2 | Dual-action compounds targeting adenosine A2A receptor and adenosine transporter for prevention and treatment of neurodegenerative diseases | ACADEMIA SINICA (TW) | 2019-07-09 | — | — | US | disclosed |
| EP-2498774-B1 | DUAL-ACTION COMPOUNDS TARGETING ADENOSINE A2A RECEPTOR AND ADENOSINE TRANSPORTER FOR PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES | ACADEMIA SINICA (TW) | 2017-10-11 | — | — | EP | disclosed |
| US-20150374737-A1 | Dual-Action Compounds Targeting Adenosine A2A Receptor and Adenosine Transporter for Prevention and Treatment of Neurodegenerative Diseases | ACADEMIA SINICA (TW) | 2015-12-31 | — | — | US | disclosed |
| US-9163057-B2 | Methods of myocardial perfusion imaging | GILEAD SCIENCES, INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-20150023867-A1 | METHODS OF MYOCARDIAL PERFUSION IMAGING | GILEAD SCIENCES, INC. (US) | 2015-01-22 | — | — | US | disclosed |
| US-20130136693-A1 | Crystal Forms of 2--Adenosine | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC (US) | 2013-05-30 | — | — | US | disclosed |
| US-20120295863-A1 | Dual-Action Compounds Targeting Adenosine A2A Receptor and Adenosine Transporter for Prevention and Treatment of Neurodegenerative Diseases | ACADEMIA SINICA (TW) | 2012-11-22 | — | — | US | disclosed |
| US-20110044904-A1 | CRYSTAL FORMS OF 2--ADENOSINE | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2011-02-24 | — | — | US | disclosed |
| US-20050209185-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-09-22 | — | — | US | disclosed |
| US-20050175535-A1 | Myocardial perfusion imaging method | CV THERAPEUTICS, INC. | 2005-08-11 | — | — | US | disclosed |
| WO-2005003150-A2 | COMPOSITIONS AND METHODS FOR USE OF A PROTEASE INHIBITOR AND ADENOSINE FOR PREVENTING ORGAN ISCHEMIA AND REPERFUSION INJURY | EMORY UNIVERSITY (US) | 2005-01-13 | — | — | WO | disclosed |
| WO-2004091596-A2 | COMBINATION THERAPIES FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-10-28 | — | — | WO | disclosed |
| US-20040209916-A1 | Combination therapies | PFIZER INC | 2004-10-21 | — | — | US | disclosed |
| EP-1397140-A2 | COMBINATION OF AN ADENOSINE A2A-RECEPTOR AGONIST AND TIOTROPIUM OR A DERIVATIVE THEREOF FOR TREATING OBSTRUCTIVE AIRWAYS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-03-17 | — | — | EP | disclosed |
| US-6599283-B1 | Method of preventing reperfusion injury | CV THERAPEUTICS, INC. | 2003-07-29 | — | — | US | disclosed |
| US-20030013675-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-01-16 | — | — | US | disclosed |
| WO-2002094273-A2 | COMBINATION OF AN ADENOSINE A2A-RECEPTOR AGONIST AND TIOTROPIUM OR A DERIVATIVE THEREOF FOR TREATING OBSTRUCTIVE AIRWAYS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150374737-A1 | Dual-Action Compounds Targeting Adenosine A2A Receptor and Adenosine Transporter for Prevention and Treatment of Neurodegenerative Diseases | ADORA2A, ADORA1, ADORA3 | EHMT1 2265/4885EHMT2 2532/4885ADORA1 2/4885 |
| US-20130136693-A1 | Crystal Forms of 2--Adenosine | ADORA2A, NT5C2, ADORA3 | EHMT1 4709/4885EHMT2 4336/4885ADORA1 4/4885 |
| US-20050209185-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | ADORA2A, ADORA3, ADORA2B | EHMT1 3927/4885EHMT2 3692/4885ADORA1 4/4885 |
| US-10342818-B2 | Dual-action compounds targeting adenosine A2A receptor and adenosine transporter for prevention and treatment of neurodegenerative diseases | ADORA2A, ADORA1, ADORA3 | EHMT1 2265/4885EHMT2 2532/4885ADORA1 2/4885 |
| US-20040209916-A1 | Combination therapies | ADRA2C, ADRB2, ADRA2A | EHMT1 2499/4885EHMT2 2012/4885ADORA1 11/4885 |
| US-20030013675-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | ADORA2A, ADORA3, ADORA2B | EHMT1 4103/4885EHMT2 3225/4885ADORA1 4/4885 |
| US-20150023867-A1 | METHODS OF MYOCARDIAL PERFUSION IMAGING | TNNI3, FABP3, TNNT2 | EHMT1 2527/4885EHMT2 1808/4885ADORA1 270/4885 |
| US-20050175535-A1 | Myocardial perfusion imaging method | ADORA2A, ADORA3, ADORA2B | EHMT1 4205/4885EHMT2 3501/4885ADORA1 5/4885 |
| US-20120295863-A1 | Dual-Action Compounds Targeting Adenosine A2A Receptor and Adenosine Transporter for Prevention and Treatment of Neurodegenerative Diseases | ADORA2A, ADORA1, ADORA3 | EHMT1 2265/4885EHMT2 2532/4885ADORA1 2/4885 |
| US-20110044904-A1 | CRYSTAL FORMS OF 2--ADENOSINE | ADORA2A, NT5C2, ADORA3 | EHMT1 4709/4885EHMT2 4336/4885ADORA1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.